Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

The FDA Has Accepted Bristol Myers Squibb's Supplemental Biologics License Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) As Potential First-line Treatment For Adult Patients With Unresectable Hepatocellular Carcinoma, With Prescription Drug User Fee Act Goal Date Of April 21, 2025

Author: Benzinga Newsdesk | August 21, 2024 07:04am

Posted In: BMY